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Abstract
Background: The Fracture Intervention Trial (FIT) showed that the bisphosphonate
alendronate reduces the risk of fractures in women with low bone mass in the United
States.
Objective:  To estimate the cost-effectiveness (cost per life-year gained and cost per
quality-adjusted life-year, QALY, gained) of treating osteoporotic women in
Denmark with alendronate, compared with no treatment.
Design: A Markov model earlier used in the economic evaluation for Sweden was
adapted using epidemiological and cost data for Denmark. In the base-case
alendronate was assumed to have a fracture-risk reducing effect for ten years; a
treatment duration period of 5 years followed by a 5-year period where the effect
declined linearly to zero.
Results: Treating a 71-year old (the mean age in the vertebral arm of the FIT)
osteoporotic woman with one prior vertebral fracture with alendronate was found to
be associated with a cost of DKK 52,311 per QALY gained. The cost-effectiveness
ratio when treating a 69-year old woman with low bone mass and without previous
vertebral fractures was higher (DKK 205,816) but still within the limits of what can
be considered good value for money.
Conclusions: The results of this study indicate that treatment with alendronate in
Denmark is cost-effective, provided the treatment is targeted towards high-risk
patients corresponding to the patient groups in the FIT study.
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Osteoporosis (bone fragility) leads to increased risk of fractures primarily of the hip,
spine and wrist in elderly (post-menopausal) women. Fosamax (alendronate) has been
shown to decrease the risk of fractures in a large US clinical trial (the FIT study). By
using a computer simulation model, we applied the clinical results from the FIT to a
hypothetical cohort of Danish women, and calculated the impact on health care costs
and quality of life (measured as quality adjusted life-years, QALYs).
We found that treatment with alendronate for women with prior vertebral fractures
leads to increased life expectancy (about 0.08 extra life-years for a treatment period of
5 years), improved quality of life (0.09 QALYs), and increased total health care costs
by less than DKK 5,000. This translates into a favourable cost-effectiveness ratio of
52,311 DKK per QALY which is well below the assumed threshold for cost-
effectiveness (about 500,000 DKK). Treating women without prior vertebral fractures
with alendronate was found to be 205,816 DKK per QALY gained.
This means that treatment with alendronate gives good value for money compared
with alternative uses for our scarce health care resources.Cost-Effectiveness of Alendronate in the Treatment of Osteoporosis in Denmark – An Economic Evaluation Based on the Fracture Intervention
Trial
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In osteoporosis the bone mass is decreased, thereby increasing the risk of fractures,
primarily of the hip, wrist and the spine [1]. Osteoporosis mainly affects elderly
women. Besides the negative impact on the quality of life of the individual it is also a
costly disease for society. The costs for osteoporosis-related fractures are expected to
increase in the future, partly due to the increasing (age-specific) incidence of fractures
and also because of changes in demographics and improved life expectancy. The
number of hip fractures in the world is estimated to increase from 1.7 million in 1990
to more than 6 million in 2050 [2, 3]. The importance of developing treatments that
reduce the fracture incidence is evident, both from an individual and a societal
perspective.
Fosamax
 (alendronate, Merck & Co., Inc.) has been shown in clinical trials to reduce
the risk of fractures by nearly one half. The largest study was called the “Fracture
Intervention Trial” (FIT), and was conducted at 11 clinical centers in the United
States and included 6 459 women with a femoral neck BMD value of 0.68 g/cm
2 or
less. The FIT consisted of two study arms; the Vertebral Fracture Arm (VFA)
including 2 027 women with radiographically identified vertebral fractures at baseline
and the Clinical Fracture Arm (CFA) with 4 432 women without vertebral fractures at
baseline.
The objective of this study is to estimate the cost-effectiveness (expressed as the cost
per quality adjusted life-year gained) of treatment with alendronate for Danish women
with osteoporosis in a societal perspective.
Cost-effectiveness is estimated in a model where the risks and costs of fracture are
defined to be relevant for Denmark. The model simulates a cohort of patients similar
to the cohort in the clinical study with respect to fracture risk and age. The analysis
focuses on the patients in the vertebral fracture arm of the FIT, i.e. women with low
BMD (femoral neck t-score of 1.6 or less) and at least one previous vertebral fracture.
Also, the cost-effectiveness of treating patients who have low BMD (femoral neck t-
score of 2.5 or less) but no earlier vertebral fracture is evaluated, based on a subgroup
of the Clinical Fracture Arm of the FIT.Cost-Effectiveness of Alendronate in the Treatment of Osteoporosis in Denmark – An Economic Evaluation Based on the Fracture Intervention
Trial
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1   Methods
1.1 Cost-effectiveness  analysis














where ∆C is the difference in total cost between interventions and no intervention,
and ∆E is the difference in effectiveness between intervention with alendronate and
no intervention.
Costs can be divided into two different categories: direct and indirect costs. Direct
costs consist of medical costs, which are costs directly attributed to health care
interventions e.g. hospitalisations, outpatient visits and drugs etc, and non-medical
costs that can be associated with provision of medical services, e.g. transportation,
home help and informal care etc.  Indirect costs are costs related to lost productivity
due to illness or treatment. Only direct costs are considered in this study since the age
of the relevant patient group will be so high that any productivity losses incurred are
negligible.  
In this study two effectiveness measures were included: life years gained and quality
adjusted life years (QALY) gained. The QALY outcome measure is the most relevant
in a health-policy perspective, since by using a common denominator it allows for
comparisons of the value of interventions across disease states.
At what costs per QALY can an intervention be considered favourable? No generally
established threshold has been established but in a survey of health economists about
the threshold value per QALY gained the mean value was US$60,000. [4] This is
equivalent to approximately DKK 500,000. In our analysis we consider any cost-
effectiveness ratio below this value to be indicative of good value for money.
1.2  A brief introduction to Markov models
Markov models are a certain type of discrete state-transition simulation models. The
simulated cohort of patients is divided into a finite number of states based on, for
example, the current health status of the patient. The states are mutually exclusive and
collectively exhaustive. The most important assumption of the Markov model is that
future events only depend on the current state the patient is in, and not on prior events
[5]. This is called the Markovian property, and means that all patients within each
state are treated the same irrespectively of their (medical) history.
Time is handled as discrete periods of the same length (cycles). Let 
i
t s  denote the
health state of patient i at time t, where
i
t s  = {1..S} and S is the number of states in the
model. The transition probability from state a to state b at time t can be written TCost-Effectiveness of Alendronate in the Treatment of Osteoporosis in Denmark – An Economic Evaluation Based on the Fracture Intervention
Trial
7
(a,b,t) = P (st = b| st-1 = a). The Markovian property requires that the transition
probability be independent of st-i for all i>1.
Markov models are a commonly used tool in medical decision analysis. The model is
especially appropriate to use when the disease in focus is characterised by recurrence
of certain events and these are based on continuous risk over time [6].
1.2.1  Half cycle correction
In the Markov model the state transitions occur at the end of the cycle. In reality
fractures occur continuously in time. If the membership is counted at the end of the
cycle the survival will be overestimated. Therefore the method of half-cycle
correction is used, by adding one extra cycle and assuming that the first and last cycle
in the model is half as long as the cycles in between the overestimation will be
corrected.
1.2.2 Cohort  simulations
Using a cohort simulation approach is the most frequently used method in Markov
model analyses. The cohort simulation considers a hypothetical cohort of persons
which all begins the process with some determined distribution among the states. In
the following cycle the cohort will be divided among the states according to transition
probabilities, which gives a new distribution of the cohort among the states. This will
continue in the subsequent cycles until the process has reached its cycle limit.
The cycle sum which is the utility or cost







s s U f
1
* (2)
Where S is the number of states,  s f  is the fraction of the cohort in state s and  s U is
the utility of state s. Appendix 1 provides a numeric example of a cycle sum
calculation.
1.2.3  Monte Carlo simulations
Another method used in Markov models is Monte Carlo simulations, which makes it
possible to perform stochastic analyses. Monte Carlo simulations take the uncertainty
in the underlying parameters of the model into account by allowing some or
preferably all of them to vary over a given range with a given distribution. By letting
a cohort go through the model a number of times a distribution of cost-effectiveness
ratios is obtained. In order to produce accurate results in Monte Carlo simulations it is
                                                





s s C f
1
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important to have good estimates of the mean and variances of the underlying
parameters [6].
1.3 Acceptability  curves
Acceptability curves can be used to capture the uncertainty surrounding the estimate
of the ICER. An acceptability curve shows the proportion of estimates of the ICER
that falls below different values of willingness to pay for one unit of health effect
(Figure 1). By assuming distributions for mean costs and mean effects the
acceptability curve can be derived using data from clinical trials, or alternatively the
distribution of the ICER can be obtained by bootstrapping from the observed samples.
Simulating effects and costs within a modelled framework, for example a Monte
Carlo Markov model, can also be used to estimate an acceptability curve. By
assigning distributions to the parameters of the model and letting the model run a
large number of times with resampling gives a distribution of the ICER.
Based on the net benefit approach Löthgren and Zethraues  [7] defined the cost-
effectiveness acceptability curve and established a formal relation between statistical
inference and the acceptability curve.
The net benefit is defined, as the incremental effect multiplied with the price society
is willing to pay per unit of effectiveness (λ), minus the incremental cost:
C E NB ∆ − ∆ ⋅ =λ λ) (       (3)
As long as the NB(λ)>0 (or equivalently ICER< λ) the intervention under scrutiny
should be implemented. If incremental cost and effects follow a bivariate normal
distribution, the net benefit will be normally distributed. Figure 2 shows the
distribution of the net benefit for different values of λ.





At each value of λ, there is possible to perform a statistical test with the null
hypothesis: H0: NB≤0, that is a non-positive net benefit (no implementation of
intervention), against the alternative hypothesis: H1: NB>0, i.e. a positive net benefit
(intervention should be implemented). Provided that the mean incremental effect is
positive, the higher the value for λ, the higher the chance that the null hypothesis will
be rejected. By plotting the proportion of the net benefit distribution greater than zero
for different values of λ (see Figure 2) the acceptability curve is obtained.Cost-Effectiveness of Alendronate in the Treatment of Osteoporosis in Denmark – An Economic Evaluation Based on the Fracture Intervention
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Figure 2 Cost-effectiveness acceptability curve
The acceptability curve shows the relation between the willingness to pay and the 1 –
P value from the hypothesis test above. For a given significance level the curve gives
information at what values of λ the intervention can be considered cost-effective. For
example if the curve is above 0.95 for all willingness to pay values exceeding DKK
1,000 then the null hypothesis (NB≤0) can be rejected at the 5% significance level.
Using a Bayesian framework instead of a frequentistic approach as above makes it
possible to interpret the acceptability curve in terms of probabilities that an
intervention is cost-effective at different values of λ. Assuming an non-informative
prior the calculation of the acceptability curve will produce the same numerical values
as in the frequentist setting.
The acceptability curve summarises in a convenient way the uncertainty surrounding
the estimate of the ICER. For the decision makers the acceptability curve can be a
useful piece of information since the willingness to pay for one more unit of health
effect is often unknown. Together with the point estimate of the incremental cost-
effectiveness ratio, the acceptability curve may be part of the standard way of
presenting results from economic evaluations in the future.
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1.4 The  model
The Markov cycle tree model in this study has been designed using DATA, a
program, which has been developed for the building of Decision tree- and Markov
models. The cycle length is one year and the structure of the model can be seen in the
state transition diagram in Figure 3.
Figure 3 Structure of the model in the analysis




Spine fracture  Wrist fracture 
There is always a probability to remain in the same state or to die, but these
transitions are excluded from the figure for simplification. All the patients begin in
the well health state. Each year a patient has a probability of having a fracture
remaining healthy or to die. If a patient dies, he will move to the dead health state and
remain there for the rest of the simulation. If he has a fracture he will move to the hip
fracture, spine fracture or wrist fracture state. After one year in one of these states the
patient can move back to the well health state, have a new fracture or die or end up in
the post hip state if he previously had a hip fracture.
A patient cannot have a spine or a wrist fracture after a hip fracture, although it is
possible to have multiple hip fractures. This assumption was made in order to simplify
the model. If wrist and spine fractures after a hip fracture would have been allowed,
two more health states would have been needed. Since the probabilities of this kind of
fractures are low, the introduction of the extra health states would not significantly
alter the results.
In this study we primarily use cohort simulations. However, in sensitivity analysis
assumptions about the distributions for some of the variables are made in order to
produce an acceptability curve, which can only be derived from a Monte Carlo





A discount rate of 3% was used for both effects and costs in the base case analysis.
All costs are in year 2000 values.
2.1.1  Cost of a Hip fracture
To estimate the cost of hospitalisation of a female hip fracture, data from inpatient
records was extracted from the database of The National Board of Health for 1000
female patients 50 years or older who suffered a hip fracture during the year 1997.
The 1000 patients were chosen randomly in the group of people with the ICD-10
codes S72.0, S72.1 and S72.2 [8] conditioned that the hip fracture had been a falling
accident and not a high-energy trauma, i.e. in the range of EUS01-EUS19 in the SKS
classification system [9]. The data set made it possible to calculate the costs of all the
patients’ hospital stays one year before and one year after the fracture. The DRG
costing system was used to assess the hospitalisation costs[10]. The mean incremental
cost of inpatient stays (CYA-CYB in table 3) is DKK 126,600. There is rather high
mortality the first year after hip fracture (>25%). The cost estimates were produced
including all patients, also those who died during the year, not to overestimate the
total cost of fracture. The part of the hip fracture costs, which are not attributed to
hospitalisations are derived from a Danish study [11, 12] by Ankjaer-Jensen et al.
They estimated that the incremental cost per patient for rehabilitation in primary care,
aids/alterations of the home and increased need for home care and nursing the year
after hip fracture was DKK 31,929. Adding this cost to the cost of hospitalisations
gives DKK 158,529, which was used as the cost of a hip fracture in the model.
The mean cost the year before fracture (CYB) and the mean cost the year after
fracture (CYA) in the sample is shown in Table 1. Both costs were rejected as
normally distributed when using the Shapiro-Wilk W´-test for normality (p-
values<0.0001)[13]. Therefore, when testing the equality of means the year before
and year after the non-parametric Wilcoxon matched-pairs signed rank test was used
[14]. The Wilcoxon test rejected the hypothesis about equality of means (p-
value<0.0001).
Table 1 Cost of hospitalisation of a hip fracture
n Mean age CYB CYA CYA-CYB P-value*
1000 81.1 35,179 161,779 126,600 <0,0001
*Wilcoxon matched-pairs signed rank testCost-Effectiveness of Alendronate in the Treatment of Osteoporosis in Denmark – An Economic Evaluation Based on the Fracture Intervention
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2.1.2  Cost the second and following years after a hip fracture
A hip fracture does not only incur costs the first year after a hip fracture but also the
second and following years. Jönsson et al calculated the post-hip cost of fracture
based on the assumption that 10% of all hip fracture patients will be long-term
admitted to nursing homes. The yearly cost of accommodation at a nursing home per
patient is DKK 290,700 [15]. This gives an average annual cost of DKK 29,070 per
hip fracture patient in the “post hip” state.
2.1.3  Cost of spine and wrist
The costs of spine and wrist fracture are assumed to be DKK 8,274 and DKK 7,188,
respectively. These are inflated estimates derived from Ankjaer-Jensen et al[11]. In
our analysis clinical vertebral fracture incidences are used, therefore the cost of spine
has been doubled since the original estimate included patients that never came to
clinical attention, which was assumed to be 50% of the patients. All fracture costs
used in the model are summarised in Table 2.
Table 2 Annual costs in the model (DKK)




2.1.4  Cost of intervention
The cost of intervention consists of drug cost and costs for monitoring bisphosfonate
therapy. The annual public drug cost of alendronate in Denmark is DKK 4,273 [16] .
The monitoring costs includes the cost of a specialist visit (DKK 1,202) [17] every
year and a Bone mineral density measurement every (DKK 500) second year,
resulting in an annual average monitoring cost of DKK 1,452 per patient. In the
model, during the intervention period, it was assumed that all patients received
medication. Thus, the annual cost of intervention was added to the incremental cost of
all health states (except health state dead) in the model. No cost of intervention
incurred after the intervention period. Both the treatment and control groups in the
FIT received calcium and vitamin D supplements, which made it possible to exclude
the costs of these agents.
2.1.5  Cost in added life years
Recently it has been argued that the difference between consumption and production
for the patients in the study should be included in cost-effectiveness analyses with a
societal perspective [18]. Individuals that work often produces more than they
consume while non-working (often elderly people) individuals consume more than
they produce. If these costs are not included in the cost-effectiveness analysisCost-Effectiveness of Alendronate in the Treatment of Osteoporosis in Denmark – An Economic Evaluation Based on the Fracture Intervention
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treatments that prolong life will be favoured compared to more quality of life
enhancing treatments in older age groups. The age-differentiated estimates of the
yearly production and consumption (public and private) in Table 3 are based on
numbers for year 2000 from the website of Statistics Denmark (www.dst.dk).
Johanneson et al. [19] estimated the yearly difference in consumption and production
for people 65 years and older in Sweden to be approximately DKK 135,600 (inflated
to year 2000 prices), which compares reasonable well with our own Danish estimate
of DKK 153,784 for the same age group. However, since our calculations are rough
estimates they are only included in the sensitivity analysis.
Table 3 Age differentiated consumption and production (DKK)
Consumption Production Consumption-Production
65-69 165,643 20,898 -144,744
70-74 153,567 4,407 -149,159
75- 162,000 1,251 -160,749
Source: Statistics Denmark and own calculations
2.2  Quality of life
Compared to a person with full health the quality of life for a person with a hip
fracture was assumed to be 0.8 the first year and 0.9 the second and following years
[20]. These weights relates closely to the estimates assessed by Hillner et al. [21].
They calculated the quality of life weight to be 0.95 the year after an uncomplicated
hip fracture, 0.76 for a disabling hip fracture and 0.36 for a fracture leading to a
nursing home placement. Assuming that the relative share of patients were 0.5, 0.4
and 0.1 respectively, the average quality of life is 0.82. For the following years the
quality weights of long-term disability and stay at nursing home were appraised to 0.8
and 0.4, which gives an average of 0.86.
The quality of life the year following spine and wrist fracture was assumed to be 0.90
and 0.95 of the quality of life of a healthy person, respectively[22]. The loss of quality
of life for wrist and spine fracture corresponds well with those recommended by the
National Osteoporosis Foundation (NOF) guidelines [23]. Brazier et al. [24] suggests
the use of generic preference based quality of life measures of 0.797 for hip fracture,
0.909 for spine fracture [25] and 0.981 for wrist fracture [26].
In the model the relative quality of life weights were compared with average
population values for the quality of life in different age groups [27]. The age-specific
quality of life weights for each health state are shown in Table 4.
Table 4 Quality of life weights in different age groups and health statesCost-Effectiveness of Alendronate in the Treatment of Osteoporosis in Denmark – An Economic Evaluation Based on the Fracture Intervention
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State 50-59 60-69 70-79 80-
Well 0,91 0,87 0,70 0,60
Hip fracture 0,73 0,70 0,56 0,48
Spine fracture 0,82 0,78 0,63 0,54
Wrist fracture 0,86 0,83 0,67 0,57
Post hip fracture 0,82 0,78 0,63 0,54
Source: [20, 27]
2.3  Risk in the model
2.3.1  Baseline risk of fracture
The age-specific risks of hip, spine and wrist fracture for Danish women were
assumed to be the same as in an observational study in Malmö, Sweden [28]. Due to
the geographic closeness, the fracture risks in Sweden should not differ significantly
from Danish fracture risks. The risks of fractures are shown in Table 5. To capture the
exponential increase in the risk of a hip fracture (see Figure 4) with age a logistic
regression was fitted to the observational data. For each age group, the middle of the
5-year interval was used in the regression. The coefficient for the intercept in the
logistic risk function was estimated to 14.19959 and the coefficient for age
0.1258271. For spine and wrist the fracture risk in each age group was the same for
the whole interval. The incidence for the age group 85-89 is used for all ages above
89 years for spine and wrist fracture while the regression is used to estimate the risk
of hip fracture above 89 years of age.
Table 5 Incidence of female osteoporotic fractures, per 1000
Age group Spine Wrist Hip
50-54 1,61 4,17 0,61
55-59 1,58 4,56 0,55
60-64 3,03 5,68 1,94
65-69 4,39 6,91 3,11
70-74 7,78 9,04 5,52
75-79 11,11 10,32 13,08
80-84 11,63 12,08 21,57
85-89 16,41 13,87 36,99
Source: [28]
Figure 4 Baseline risk of fractureCost-Effectiveness of Alendronate in the Treatment of Osteoporosis in Denmark – An Economic Evaluation Based on the Fracture Intervention
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2.3.2  Risk reduction of alendronate
The FIT-trial was a US based study including women. No similar study has been
conducted in Denmark, therefore it is assumed that alendronate has the same effect on
Danish women with the same characteristics as the patients in the FIT. In Table 6 the
fracture-specific relative risk reductions of alendronate in the 3-year Vertebral
Fracture Arm and the 4,2-year subgroup of the Clinical Fracture Arm of the FIT is
presented [29, 30]. In the base-case the treatment period is assumed to be 5 years,
with a following 5-year period where the effect of treatment declines linearly to zero.
This period of loss is called “set time” period [22]. Figure 5 illustrates how the
treatment and set-time period is structured in the model. In sensitivity analysis we
tested a 10-year treatment period and a longer set-time of 10 years. The relative risk
reductions, which in the FIT are based on 3 and 4,2-year treatment with alendronate,
are assumed to be the same reductions that would be observed after 5 and 10 years of
treatment. This is a rather conservative assumption since no benefit is added for the
extra years of treatment.
Table 6 Fracture-specific relative risk reduction alendronate in the FIT
Fracture type Vertebral arm Clinical arm
Hip 0.51 0.56
Wrist 0.48 0
Clinical vertebral 0.54 0
Source: [29]
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2.3.3  Relative risk of fracture for persons meeting FIT inclusion criteria
To make an accurate analysis based on the clinical trial, the simulated cohort in the
model should have the same risk of fracture as the subjects in the FIT. By calculating
the ratio for the risk of fracture in the FIT-group and the general US female
population the relative risk of fracture is obtained. The fracture-specific relative risks
for the VFA and the subgroup of the CFA studies are presented in Table 7.
Table 7 Relative risk of fracture


























Hip 0.0077 0.0053 0.0029 2.63 1.81
Vertebral 0.0176 0.0041 0.0074 2.40 0.56
Wrist 0.0144 0.0113 0.0072 1.99 1.80
* risk is one year risk


















































Patients who did not suffer any hip fractures in the model were assumed to have the
same mortality rates as the general population [25]. The general population mortality
rates are shown in Table 8. After suffering a hip fracture the mortality rate is higher
than the normal. The mortality rates the year after a hip fracture, presented in Table 9,
used in this analysis are deduced from the data set from The National Board of
Health, which contained information about the patients’ possible event of death the
year after fracture. The mortality rates for the post-hip, spine and wrist health states
are assumed to be the same as in the general population.
Table 8 Normal mortality for women in Denmark (per 1000)
50 3.79 60 9.74 70 23.76 80 60.10 90 183.95
51 4.16 61 10.62 71 25.64 81 66.28 91 204.56
52 4.42 62 11.76 72 28.25 82 74.63 92 230.17
53 4.79 63 13.06 73 30.45 83 83.40 93 254.18
54 5.47 64 14.28 74 33.08 84 93.68 94 288.70
55 5.97 65 15.53 75 36.51 85 104.71 95 304.88
56 6.59 66 16.79 76 40.33 86 115.79 96 346.96
57 7.41 67 18.59 77 44.14 87 131.76 97 371.62
58 7.87 68 19.50 78 48.05 88 148.42 98 408.30
59 8.65 69 21.74 79 53.77 89 162.55 99 489.61
Source: [31]
Table 9 Mortality the year after hip fracture






The mean age in the Vertebral Fracture Arm of the FIT was 71 years, which is used as
the starting age for the cohort in the base-case. The standard deviation of the age in
the FIT was 5,6 years, which implies that approximately 70% of the patients in the
study were between 65 and 77 years. These ages are used as starting ages in
sensitivity analysis. In the Clinical Fracture Arm the mean age was 69 years, with a
standard deviation of approximately 6 years. At all starting ages the cohort is




3.1 Base-case  simulation
3.1.1  Estimated risk of fracture
The expected number of fractures per patient when treated with alendronate and given
no treatment for the Vertebral Fracture Arm scenario is shown in Table 10. A longer
study perspective results in proportionally fewer prevented fractures, which is
expected since treatment duration and set-time were both 5 years in the base-case.
Table 10 Expected number of fractures
10-year perspective Lifetime perspective
Strategy hip verteb. wrist hip verteb. wrist
Untreated 0.16 0.15 0.13 0.42 0.22 0.18
Alendronate 0.10 0.08 0.08 0.36 0.16 0.14
3.1.2 Cost  analysis
The discounted expected lifetime cost of all fractures, shown in Table 11, for a 71
year old woman with previous vertebral fractures and low bone mass (VFA) was
calculated to be DKK 105,054. Treatment with alendronate in the 5-year intervention
base-case would provide DKK 19,880 in savings and the cost of the intervention
would be DKK 24,785, which results in an incremental cost of DKK 5,759. The total
discounted cost per patient administered alendronate, i.e. the expected lifetime costs
plus the incremental cost, would be DKK 109,958.
Table 11 Cost analysis, discount rate 3% (DKK)
Vertebral Fracture Arm Clinical Fracture Arm
Expected lifetime fracture costs 105,054 74,353
without intervention
Saved cost of fracture 19,880 13,133
Cost of intervention 24,785 25,073
Incremental cost 4,905 11,940
Total cost 109,958 86,293Cost-Effectiveness of Alendronate in the Treatment of Osteoporosis in Denmark – An Economic Evaluation Based on the Fracture Intervention
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3.1.3 Cost-effectiveness  analysis
Results of the cost-effectiveness analysis are presented in Table 12. The cost per
QALY gained for 5-year intervention of alendronate was DKK 52,311 for the VFA
and DKK 205,816 for the subgroup of the CFA, which is below the assumed
threshold value of DKK 500,000 per QALY gained for a treatment to indicate good
value for money. The cost-effectiveness of alendronate for a woman without any prior
vertebral fractures is worse compared to a woman with prior fractures. This is mainly
because the lower risk of fracture for this patient type.
Table 12 Cost-effectiveness analysis
Vertebral Fracture Arm Clinical Fracture Arm
Incremental cost DKK 4,905 DKK11,940
Life-years gained 0.0818 0.05145
Cost per life-year gained DKK 60,000 DKK 232,078
QALYs gained 0.09376 0.05801
Cost per QALY gained DKK 52,311 DKK 205,816
3.1.4 Acceptability  curve
To capture some of the uncertainty in the cost per QALY gained some Monte-Carlo
simulations were undertaken for the base case. To perform a Monte-Carlo simulation
distributions have to be attributed to the parameters used in the model.  The hip
fracture cost was assumed to have a log normal distribution, mean and standard error
was calculated by taking the logarithm of the patients´ incremental costs of inpatient
stays in the database from The National Board of Health. Wrist, vertebral and
“posthip” fracture costs were assumed to be uniformly distributed, the endpoints of
their inter-quartile ranges were used as min and max values.  Since the risk reduction
of alendronate for the different fractures was estimated with non-parametric methods
[29] a triangular distribution was judged to best capture the asymmetric data. The
confidence intervals of the fracture-specific risk reductions were used as min and max
values.
In Figure 6 acceptability curves derived from Monte-Carlo simulations with 1000
iterations are presented for the Vertebral and the Clinical Fracture Arm. For women
with prior vertebral fractures the cost-effectiveness ratio was below the threshold
value 933 times out of the1000 iterations, or equivalently at a significance level of 6.7
% the null hypothesis of a non-positive net benefit is rejected at a willingness to pay
of DKK 500,000. In 201 times out of 1000 (where the curve crosses the y-axis)
alendronate dominated the no treatment alternative, i.e. lower costs and higher quality
gains. For the clinical fracture arm patients the hypothesis of a positive net benefit
could be accepted at a significance level of 16%, i.e. the cost-effectiveness ratio was
below the threshold value 840 times out of the 1000 iterations.
The results of the acceptability curve have to be interpreted with some caution.
Distributions were not attributed to all parameters in the model (only effects and
fracture costs) and any covariation between the parameters was not available.Cost-Effectiveness of Alendronate in the Treatment of Osteoporosis in Denmark – An Economic Evaluation Based on the Fracture Intervention
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Although the curves do not capture all of the uncertainty in the cost-effectiveness
estimates it captures some, which could be valuable information for decision-makers.
Figure 6 Acceptability curves
3.2 Sensitivity  analysis
3.2.1  Length of intervention
When the intervention period was extended to 10 years, the cost-effectiveness ratio
was higher compared to the base-case (Table 13). The main reason is that mortality
increases and quality of life decreases with age. Thus the cost savings and the
outcome do not increase proportionally to the increase in cost of treatment.
Table 13 Sensitivity analysis: 10-year intervention
Vertebral Fracture Arm Clinical Fracture Arm
Incremental cost DKK 10,804 DKK 21,568
Life-years gained 0.1485 0.09621
Cost per life-year gained DKK 72,778 DKK 224,181
QALYs gained 0.15788 0.10207













































As can be seen in Table 14 the cost per QALY gained improves when the effect of
treatment was assumed to decline linearly over 10 years instead of 5 years after the
intervention period. This is expected since the effect of alendronate diminishes over a
longer time period while the cost of intervention is the same.
Table 14 Sensitivity analysis: 10 years set- time
Vertebral Fracture Arm Clinical Fracture Arm
Incremental cost DKK   768 DKK    7,646
Life-years gained 0.1150 0.07379
Cost per life-year gained DKK 6,678 DKK 103,619
QALYs gained 0.12554 0.07992
Cost per QALY gained DKK 6,116 DKK   95,661
3.2.3  Starting age of cohort
When the starting age of the cohort is one standard deviation above the mean age
treatment with alendronate is both more efficient and less costly than no treatment for
both women with and without prior fractures (Table 15). At the lower starting age the
cost per QALY gained is markedly higher. This is not surprising since the baseline
risk for fracture is lower at this age (consider the increase in risk of hip fracture by
age in figure 5).  In Figure 7, which shows the cost per QALY gained at different
starting ages of the cohort and assumed set-times of 0, 3, 5 and 10 years for women
with prior vertebral fractures, it easy to see that longer set-times and higher starting
ages gives lower cost-effectiveness ratios. When making the conservative assumption
of no set-time, i.e. no effect of alendronate after the treatment period, the cost per
QALY gained is below the threshold for starting ages of 65 years and above.
Table 15 Sensitivity analysis: Different starting ages
Incremental cost QALYs gained Cost per QALY gained
VFA: Starting age 65 DKK 13,061 0.05899 DKK 221,418
VFA: Starting age 77 DKK  -4,573 0.15107 Dominating
CFA: Starting age 63 DKK 14,475 0.04412 DKK 334,179
CFA: Starting age 75 DKK     -911 0.12524 DominatingCost-Effectiveness of Alendronate in the Treatment of Osteoporosis in Denmark – An Economic Evaluation Based on the Fracture Intervention
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Figure 7 Sensitivity analysis: Different starting ages and set-times
3.2.4  Relative risk of hip fracture
Figure 8 shows the cost per QALY gained at different levels of relative risk of hip
fracture holding the relative risk of wrist and vertebral fracture constant. Assuming a
relative risk of one, which is equal to the baseline risk, the cost-effectiveness is above
the assumed threshold for patients without prior vertebral fractures.
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3.2.5  Cost in added life years
The cost-effectiveness ratios are higher when cost in added life years are included in
the analysis (Table 16). Alendronate has a prolonging effect on life compared to no
treatment and this gain in extra lifetime is associated with costs for the society since
the age group in focus consumes more than they produce. The inclusion of cost in
added years of life increases the cost-effectiveness ratio, but it will also increase the
“bench-mark” value for good “value for money”. The inclusion of these costs will
thus not change the conclusions, but will have consequences for the rankings of
programs which are mainly life saving compared to those that mainly improve quality
of life.
Table 16 Cost-effectiveness including cost in added life years
Vertebral Fracture Arm Clinical Fracture Arm
Incremental cost DKK 18,014 DKK 20,147
Life-years gained 0.0818 0.05145
Cost per life-year gained DKK 220,366 DKK 391,604
QALYs gained 0.09376 0.05801




As in all modelling exercises, several assumptions were made in this study leading to
uncertainties in the results. Despite the fact that sensitivity analyses were conducted
to address them, there are still limitations that have to be considered.
The risks used in the model are total risks, i.e. not the risk of having a first fracture
but the total number of fractures during the year divided by the number of patients.
This means that this risk has to be applied to the entire cohort (except for the dead, of
course) in order to produce the correct number of fractures. This is reflected in the
way the model is constructed. In each cycle, every patient who is alive is exposed to
the risk of fracture. The only deviation from this principle is that patients who have
had a hip fracture will no longer be exposed to the risk of spine- or wrist fracture.
This assumption is made in order to simplify the model. To allow for these fractures,
two new states would have to be introduced, but the results would not be significantly
different since the probability of this event is very low.  The current model, thus,
slightly underestimates the number of spine- and wrist fractures and is thereby
possibly conservative with respect to the effectiveness of treatment with alendronate.
The cost of treating a fracture increases with the age of the patient [32]. Introducing
age dependent costs of fractures would have improved the model. However, the
change in cost-effectiveness ratios would likely to be marginal.
In the analysis a compliance rate of 100% was assumed. However, in the vertebral
and clinical fracture arm of the FIT, 87% and 84% of the placebo group and 89% and
83% of the alendronate group were still taking medication at the time of closeout. The
assumption of full compliance in the model likely leads to overestimated intervention
costs in relation to the assumed effectiveness of treatment, which included non-
compliers in the FIT. In real clinical practice the compliance is almost never full,
which leads to lower effectiveness, however this is somewhat balanced by a lower
intervention cost.
There was no significant difference in adverse experiences between treatment groups
in the FIT, and therefore no adjustments on costs or quality of life for side effects
were included in the model.
In the base case a five-year decline, i.e. set-time, of the effect of alendronate after
discontinue of treatment was assumed. There is evidence that the effect of alendronate
may also remain after the cessation of therapy. In a study by Stock et al. [33] the
difference in bone density between the alendronate and placebo groups at the end of
trial was maintained for up to two years. Thus a 10-year set-time, which was tested in
a sensitivity analysis, may be a more suitable assumption since no accelerated bone
loss is observed after discontinuation of treatment.
The cost-effectiveness ratios were lower than the assumed threshold value of DKK
500,000 per QALY gained for patients with and without prior vertebral fractures.
Except for a few of the scenarios in the sensitivity analysis the cost per QALY gained
remained below the threshold value. Even at a more conservative threshold value ofCost-Effectiveness of Alendronate in the Treatment of Osteoporosis in Denmark – An Economic Evaluation Based on the Fracture Intervention
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DKK 335,000 ($40,000), which has been suggested in the literature [34, 35]
alendronate is cost-effective for the majority of the scenarios.
Taking the above-mentioned limitations and uncertainties in consideration the
conclusion is that the results in this study indicate that alendronate is cost-effective
for the treatment of high-risk women in Denmark. This means that, compared with
alternative uses of scarce health care resources, treatment with alendronate gives a
comparatively high health benefit (improvement in quantity and/or quality of life) for
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Appendix 1. Example cycle-sum calculation
The structure of the model used in the example is displayed in the Markov cycle tree
in Figure A:1.
Figure A: 1 Markov cycle tree
Attached to the Markov node are branches, which define the health states in the
model. From the health states stem the terminal nodes, which define the allowed
transitions from each state. At each terminal node the estimated transition probability
is defined. A person is always in a state and during each cycle he has some certain
probabilities to make one transition between the defined states. A person in the Well
state can make transitions to all the three states but a person who ends up in the Dead
state can not make any further transitions. The transition probabilities can be time
dependent, e.g. they can change for different ages. To terminate the Markov process
an absorbing state is needed, that is a state, which the person cannot leave. In the
above example the Dead state is an absorbing state. There is an option between letting
the cohort run through a certain number of cycles (e.g. up to a specific age) or let the
process terminate when a predetermined share of the cohort has ended up in the
absorbing state.
Calculation of the cycle-sum based on the Markov cycle tree and the health state
utilities presented in Table A:1 is shown in Table A:2.
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Table A: 2 Example of cycle sum calculations
Cycle Well Disabled Dead Cycle sum Cumulative Utility
Start 1000 0 0 (1000*1)/2=500 500
1 600 200 200 (600*1+200*0.7+200*0)=740 1240
2 480 160 360 (480*1+160*0.7+360*0)=592 1832
3 384 128 488 (384*1+128*0.7+488*0)=474 2306
** * * * *
19 11 4 985 (11*1+4*0.7+985*0)=14 4146
20 9 3 988 (9*1+3*0.7+988*0)/2=6 4152
The hypothetical cohort is 1000 persons
2 which all begins in the Well state. In the
following cycle simulations the cohort is distributed among the states according to the
transition probabilities. For example, the number of patients in the Well, Disabled and
Dead states in cycle 2 are obtained by multiplying the number of alive patients in the
in the preceding cycle with its transition probabilities, i.e. 800*0.6=480 for the Well
state, 800*0.2=160 for the Disabled and Dead states.  The accumulative number of
dead of the original 1000 persons adds up to 360 in cycle 2. The process is set to
terminate after 20 cycles. The number of patients in each state times the respective
state utility adds up to the cycle sum. The cycle sum in the first and the last cycle is
divided by two due to half cycle correction. The running total of the cycle sum is
called the cumulative utility.
                                                
2 The number of people in the cohort is actually irrelevant for the results in the model, since it is the
incremental utility and cost that is important in the cost-effectiveness analysis.